It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

¹**A meta-analysis on the role of pre-existing chronic disease in the cardiac complications** ²**of SARS-CoV-2 infection**

 $\frac{3}{4}$

- Jane E. Sinclair¹, Yanshan Zhu¹, Gang Xu², Wei Ma^{3,4}, Haiyan Shi⁵, Kun-Long Ma⁶, Chun-Feng Cao⁶, Ling-Xi
5 Kong⁶, Ke-Qiang Wan⁶, Juan Liao⁶, Hai-Qiang Wang⁷, Matt Arentz⁸, Meredith Redd¹², Linda A 6 Kirsty R. Short^{1, $I4*$}
- ¹ School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
8² Guangzhou First People's Hospital, Guangzhou, Guangdong, China
- ² Guangzhou First People's Hospital, Guangzhou, Guangdong, China 8 — ² Guangzhou First People's Hospital, Guangzhou, Guangdong, China
9 — ³ Department of Geriatric Medicine. Guangzhou First People's Hospit
- 9 Chepartment of Geriatric Medicine, Guangzhou First People's Hospital, Guangzhou, Guangdong, China 9 and 4 School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
-
- ⁴ School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
11⁵ Department of Respiratory Medicine, Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
12⁶ Yongchuan Hospital o
- ⁶ 12⁶ 16 12Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing, China

⁷ Institute of Integrative Medicine, Shaanxi University of Chinese Medicine, Xi'an Shaan
- ⁷ Institute of Integrative Medicine, Shaanxi University of Chinese Medicine, Xi'an Shaanxi Province, China
14 ⁸ Department of Global Health. University of Washington, Seattle, Washington, U.S.A.
- ⁸ Department of Global Health, University of Washington, Seattle, Washington, U.S.A. ⁸ Department of Global Health, University of Washington, Seattle, Washington, U.S.A.
15 ¹² Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
-
- ¹² Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia 16¹³ School of Biomedical Sciences, The University of Queensland, Brisbane, Australia 17¹⁴ School of Public Health. The Univers
- 17 ¹⁴ School of Public Health, The University of Queensland, Brisbane, Australia
18 *** Correspondence:** k.short@ug.edu.au: Tel.: +61 7 336 54226
- ¹⁸*** Correspondence:** k.short@uq.edu.au; Tel.: +61 7 336 54226

-
- 21
-
-
- 23
- 24
-
-
-
- 26
-
-
- 28
-
- 29

It is made available under a CC-BY-NC-ND 4.0 International license.

³⁰**SUMMARY**

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with
32 multiple direct and indirect cardiovascular complications. It is not vet well defined whether the patient groups at 32 multiple direct and indirect cardiovascular complications. It is not yet well defined whether the patient groups at
33 increased risk of SARS-CoV-2 severe respiratory disease experience similarly heightened incidence of 33 increased risk of SARS-CoV-2 severe respiratory disease experience similarly heightened incidence of
34 cardiovascular complications. We sought to analyse the role of host co-morbidities (chronic respiratory 34 cardiovascular complications. We sought to analyse the role of host co-morbidities (chronic respiratory
35 illnesses, cardiovascular disease (CVD), hypertension or diabetes mellitus (DM)) in the acute cardiovascular 35 illnesses, cardiovascular disease (CVD), hypertension or diabetes mellitus (DM)) in the acute cardiovascular complications associated with SARS-CoV-2 infection. complications associated with SARS-CoV-2 infection.

37 Methods: We retrospectively investigated published and pre-printed, publicly released, de-identified, data
38 made available between Dec 1, 2019, and October 14, 2020. Information was accessed from PubMed. Embase. 38 made available between Dec 1, 2019, and October 14, 2020. Information was accessed from PubMed, Embase,
39 medRxiv and SSRN. 363 full-text articles were reviewed and 283 excluded for lack of original research. 39 medRxiv and SSRN. 363 full-text articles were reviewed and 283 excluded for lack of original research,
40 irrelevance to outcome, inappropriate cohort, or describing case reports of <10 patients. Data were extracted 40 irrelevance to outcome, inappropriate cohort, or describing case reports of <10 patients. Data were extracted 41 from 25 studies and the remaining 55 contacted to request appropriate data, to which four responded with d 41 from 25 studies and the remaining 55 contacted to request appropriate data, to which four responded with data
42 contributions. A final of 29 studies were included. This systematic review was conducted based on Preferre 42 contributions. A final of 29 studies were included. This systematic review was conducted based on Preferred
43 Reporting Items for Systematic Reviews (PRISMA) and Meta-analyses of Observational Studies in 43 Reporting Items for Systematic Reviews (PRISMA) and Meta-analyses of Observational Studies in
44 Epidemiology (MOOSE) statements. Included studies were critically appraised using Newcastle Ottawa Ouality 44 Epidemiology (MOOSE) statements. Included studies were critically appraised using Newcastle Ottawa Quality
45 Assessment Scale (NOS). Data were extracted independently by multiple observers. When $I^2 \square \le 50\%$. a Assessment Scale (NOS). Data were extracted independently by multiple observers. When $I^2 \square \ll \square 50\%$, a 46 fixed effects model was selected, while a random-effects model was employed when $I^2 \square > 50\%$. fixed effects model was selected, while a random-effects model was employed when $I^2 \square > 50\%$.
47 Cardiovascular complications were measured as blood levels of cardiac biomarkers above the 99th percentile 47 Cardiovascular complications were measured as blood levels of cardiac biomarkers above the 99th percentile
48 upper reference limit, new abnormalities in electrocardiography, and/or new abnormalities in echocardiography upper reference limit, new abnormalities in electrocardiography, and/or new abnormalities in echocardiography.

Results: Individual analyses of the majority of studies found that the median age was higher by approximately $50 - 10$ vears in patients with cardiovascular complications. Pooled analyses showed the development of SARS-50 10 years in patients with cardiovascular complications. Pooled analyses showed the development of SARS-
51 CoV-2 cardiovascular complications was significantly increased in patients with chronic respiratory illness 51 CoV-2 cardiovascular complications was significantly increased in patients with chronic respiratory illness
52 (Odds Ratio (OR) 1.6711.48.1.881). CVD (OR 3.3712.57.4.431). hypertension (OR 2.6812.11.3.411). DM (OR 52 (Odds Ratio (OR) 1.67[1.48,1.88]), CVD (OR 3.37[2.57,4.43]), hypertension (OR 2.68[2.11,3.41]), DM (OR 53 1.60[1.31,1.95]) and male sex (OR 1.31[1.21,1.42]), findings that were mostly conserved during sub-analysis of 53 1.60[1.31,1.95]) and male sex (OR 1.31[1.21,1.42]), findings that were mostly conserved during sub-analysis of
54 studies stratified into four global geographic regions. studies stratified into four global geographic regions.

55 **Conclusions:** Age, chronic respiratory illness, CVD, hypertension, DM and male sex may represent prognostic
56 factors for the development of both acute and chronic cardiovascular complications in COVID-19 disease, 56 factors for the development of both acute and chronic cardiovascular complications in COVID-19 disease,
57 highlighting the need for a multidisciplinary approach to chronic disease patient management. highlighting the need for a multidisciplinary approach to chronic disease patient management.

-
-
-
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁶²**INTRODUCTION**

63 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and has since gone
64 on to cause the ongoing coronavirus disease 2019 (COVID-19) pandemic, infecting >50 million people 64 on to cause the ongoing coronavirus disease 2019 (COVID-19) pandemic, infecting >50 million people
65 worldwide. SARS-CoV-2 causes a broad range of respiratory symptoms, ranging from subclinical disease to 65 worldwide. SARS-CoV-2 causes a broad range of respiratory symptoms, ranging from subclinical disease to
66 viral pneumonia [1]. However, it is increasingly apparent that SARS-CoV-2 also causes a variety of extra-66 viral pneumonia [1]. However, it is increasingly apparent that SARS-CoV-2 also causes a variety of extra-
67 respiratory complications [1]. Specifically, SARS-CoV-2 infection has been associated with acute myocardial 67 respiratory complications [1]. Specifically, SARS-CoV-2 infection has been associated with acute myocardial injury, myocarditis, arrhythmias, venous thromboembolism and other cardiac complications [2–6]. The 68 injury, myocarditis, arrhythmias, venous thromboembolism and other cardiac complications [2–6]. The development of these complications is likely enhanced by experimental testing of antimalarial and antiviral 69 development of these complications is likely enhanced by experimental testing of antimalarial and antiviral
70 drugs, which have known cardiovascular side effects [4–12]. Although prevalence estimates vary, data from 70 drugs, which have known cardiovascular side effects [4–12]. Although prevalence estimates vary, data from
71 China suggests that approximately 7% of patients infected with SARS-CoV-2 develop cardiac injury (defined as 71 China suggests that approximately 7% of patients infected with SARS-CoV-2 develop cardiac injury (defined as
72 elevated high-sensitivity cardiac troponin I or new echocardiographic: electrocardiographic (ECG) 72 elevated high-sensitivity cardiac troponin I or new echocardiographic; electrocardiographic (ECG)
73 abnormalities) [13] This prevalence increases to 25% in those hospitalised with COVID-19 [14], and 22% in 73 abnormalities) [13]. This prevalence increases to 25% in those hospitalised with COVID-19 [14], and 22% in
74 patients who required intensive care unit (ICU) admission [13]. However, at present, the role of pre-existing 74 patients who required intensive care unit (ICU) admission [13]. However, at present, the role of pre-existing
75 chronic disease in the cardiac complications of COVID-19 remains to be elucidated. 75 chronic disease in the cardiac complications of COVID-19 remains to be elucidated.
76

77 77 Pre-existing chronic respiratory disease, cardiovascular disease (CVD), hypertension and diabetes mellitus
78 (DM) have each been associated with increased rates of hospitalization. ICU admission, and death from the 78 (DM) have each been associated with increased rates of hospitalization, ICU admission, and death from the respiratory complications of SARS-CoV-2 [13–27]. It is not vet well defined whether these patient groups are 79 respiratory complications of SARS-CoV-2 [13–27]. It is not yet well defined whether these patient groups are
80 also at an increased risk of SARS-CoV-2 associated cardiac injury. Some small studies have shown that patie 80 also at an increased risk of SARS-CoV-2 associated cardiac injury. Some small studies have shown that patients
81 with pre-existing CVD are at a higher risk of myocarditis and/or myocardial infarction (MI) from SARS-CoV 81 with pre-existing CVD are at a higher risk of myocarditis and/or myocardial infarction (MI) from SARS-CoV-2
82 [3, 28, 29]. A retrospective, single-centre case series of 187 patients with COVID-19 also found that pre-82 [3, 28, 29]. A retrospective, single-centre case series of 187 patients with COVID-19 also found that pre-
83 existing CVD increased the risk of cardiac injury (as defined by troponin elevation) (54.5% vs 13.2%) and 83 existing CVD increased the risk of cardiac injury (as defined by troponin elevation) (54.5% vs 13.2%) and
84 mortality compared with patients without CVD [3]. Similarly, a meta-analysis of 28 observational studies found 84 mortality compared with patients without CVD [3]. Similarly, a meta-analysis of 28 observational studies found
85 SARS-CoV-2 associated cardiac injury biomarkers to be related to a history of hypertension but not DM [30 85 SARS-CoV-2 associated cardiac injury biomarkers to be related to a history of hypertension but not DM [30]. In
86 contrast. Zhu and colleagues found that individuals with type 2 DM had a greater occurrence of acute hear 86 contrast, Zhu and colleagues found that individuals with type 2 DM had a greater occurrence of acute heart 87 iniury (7.3% versus 3.0%) than individuals without DM [31]. injury (7.3% versus 3.0%) than individuals without DM [31].

88 There is a clear need to better understand the role of patient host factors in the extra-respiratory complications of
89 SARS-CoV-2 infection. Here, we analysed the currently available literature on the role of pre-exis 89 SARS-CoV-2 infection. Here, we analysed the currently available literature on the role of pre-existing chronic
90 respiratory illnesses, CVD, hypertension and DM in the prevalence of SARS-CoV-2 associated cardiac injury

90 respiratory illnesses, CVD, hypertension and DM in the prevalence of SARS-CoV-2 associated cardiac injury.
91

-
- 92
- 92
- 94
- 95
- 95
- 97
- 98
- 98

It is made available under a CC-BY-NC-ND 4.0 International license.

¹⁰⁰**METHODS**

102 ¹⁰²*Study selection*

103 We retrospectively investigated published and pre-printed, publicly released and de-identified data made
104 available between Dec 1.2019. and October 14.2020. Information was accessed from four databases (PubMed. 104 available between Dec 1, 2019, and October 14, 2020. Information was accessed from four databases (PubMed,
105 Embase, medRxiv and SSRN) using the following search terms: ("covid-19"[All Fields]) OR ("SARS-CoV-105 Embase, medRxiv and SSRN) using the following search terms: ("covid-19"[All Fields]) OR ("SARS-CoV-
106 2"[All Fields]) AND ("cardiac"[All Fields] AND "comorbid*"[All Fields]). A total of 1076 articles were 106 2"[All Fields]) AND ("cardiac"[All Fields] AND "comorbid*"[All Fields]). A total of 1076 articles were
107 retrieved after duplicates were removed (available in either English or Chinese), following which 713 records 107 retrieved after duplicates were removed (available in either English or Chinese), following which 713 records
108 were removed after screening by title and abstract. 363 full-text articles were reviewed. Of these, 283 108 were removed after screening by title and abstract. 363 full-text articles were reviewed. Of these, 283 articles were rexcluded because i) they did not include original research. ii) they were not relevant to the outco were excluded because i) they did not include original research, ii) they were not relevant to the outcome, iii)
110 they described an inappropriate patient population and/or iv) they described case reports of <10 patients 110 they described an inappropriate patient population and/or iv) they described case reports of <10 patients. Of the
111 remaining 80 studies that were deemed eligible, due to their containing data on patient pre-existing 111 remaining 80 studies that were deemed eligible, due to their containing data on patient pre-existing disease and
112 cardiac complications as an outcome. 25 contained the required data format and these were extracted. 112 cardiac complications as an outcome, 25 contained the required data format and these were extracted. The authors of the remaining 55 studies were contacted to request appropriate data (as they presented only aggregate 113 authors of the remaining 55 studies were contacted to request appropriate data (as they presented only aggregate
114 data that did not specify the cross-over between pre-existing chronic disease and outcome), to which 114 data that did not specify the cross-over between pre-existing chronic disease and outcome), to which four groups
115 responded with data contributions. Thus, a final of 29 studies were included in the meta-analysis [3. 115 responded with data contributions. Thus, a final of 29 studies were included in the meta-analysis [3,4,29,32-57].
116 The selection process is shown in Figure 1. 116 The selection process is shown in Figure 1.
117

118 ¹¹⁸*Data extraction and analysis*

119 Extracted variables were aggregate data of median age, sex, underlying chronic disease (chronic respiratory
120 illness, CVD, hypertension and DM) and the occurrence of cardiac complications as an outcome. Patients wit 120 illness, CVD, hypertension and DM) and the occurrence of cardiac complications as an outcome. Patients with
121 co-morbidities were included in all applicable categories. For cases in which the data source reported mor 121 co-morbidities were included in all applicable categories. For cases in which the data source reported more than
122 one type of co-morbid CVD separately (such as prevalence of both chronic heart failure and coronary h 122 one type of co-morbid CVD separately (such as prevalence of both chronic heart failure and coronary heart 123 disease within their cohort), only the group with the largest number of cases was included to avoid patient 123 disease within their cohort), only the group with the largest number of cases was included to avoid patient
124 double up and overrepresentation of co-morbid CVD. Analyses for each co-morbidity were performed 124 double up and overrepresentation of co-morbid CVD. Analyses for each co-morbidity were performed
125 independently, with each assuming one effect (the patient group in question) is considered as the main driver 125 independently, with each assuming one effect (the patient group in question) is considered as the main driver
126 of effects. Median data for age were analysed individually using a Mann-Whitney U test. R version 4.0.0 126 of effects. Median data for age were analysed individually using a Mann-Whitney U test. R version 4·0·0
127 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac outcomes 127 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac outcomes through meta analysis. Heterogeneity among studies was assessed by using the O statistic with *P<0.05 128 through meta \Box analysis. Heterogeneity among studies was assessed by using the Q statistic with **P* \leq 0.05 indicating the presence of significant heterogeneity and quantified by using the *I*² statistic. A fixed indicating the presence of significant heterogeneity and quantified by using the *I*² statistic. A fixed-effects model was used as when $I^2 \square \le \square 50\%$ and random-effects model when $I^2 \square \ge \square 50\%$. 130 model was used as when $I^2 \square \leq 50\%$ and random-effects model when $I^2 \square \geq 50\%$.

131
132

¹³²*Definition of cardiac complications*

133 Cardiac complications were defined as one or more of the following: blood levels of cardiac biomarkers 134 (troponin I or creatine-kinase myocardial band) above the $99th$ percentile upper reference limit [58–60]

(troponin I or creatine-kinase myocardial band) above the $99th$ percentile upper reference limit [58–60], and/or abnormalities observed in clinical assessments of the patients' heart function, including ECG [61–65]

- 135 abnormalities observed in clinical assessments of the patients' heart function, including ECG [61–65] or
136 echocardiography [62–66].
- 136 echocardiography [62–66].
137
-

138 ¹³⁸*Quality assessment and data synthesis*

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a CC-BY-NC-ND 4.0 International license.

176 **RESULTS**
177 *SARS-CoV-*

¹⁷⁷*SARS-CoV-2 patients with pre-existing chronic illnesses are at increased risk of acute cardiac complications*

178 179 We identified 1076 articles that described pre-existing chronic disease and cardiac complications of SARS-
180 CoV-2, rejected 996 articles due to a lack of sufficient and/or appropriate data and derived a total of 80 180 CoV-2, rejected 996 articles due to a lack of sufficient and/or appropriate data and derived a total of 80 articles.
181 29 of these studies were subsequently used in a meta-analysis (Figure 1), all of which were high 181 29 of these studies were subsequently used in a meta-analysis (Figure 1), all of which were high quality (Table 182 1). Baseline characteristics of the patient populations as well as other relevant data are listed in T 182 1). Baseline characteristics of the patient populations as well as other relevant data are listed in Table 2. The definition of cardiac complications varied between studies, ranging from acute cardiac injury to fulmina 183 definition of cardiac complications varied between studies, ranging from acute cardiac injury to fulminant
184 myocarditis. 20 studies measured cardiac outcomes on the day of admission [3,29,32,34,35,37–41,43–48,50-184 myocarditis. 20 studies measured cardiac outcomes on the day of admission [3,29,32,34,35,37–41,43–48,50-
185 52,571, and one at the time of patient death [33], with the remaining eight studies not specifying the time o 185 52,57], and one at the time of patient death [33], with the remaining eight studies not specifying the time of 186 assessment [4,36,42,49,53–55]. The studies were conducted in 10 countries in four geographical location 186 assessment [4,36,42,49,53–55]. The studies were conducted in 10 countries in four geographical locations (U.S.A. [32,33,41,48,49], the Middle East [34,50,52], Europe [4,35–40,44,45,47], and the People's Republic of 187 (U.S.A. [32,33,41,48,49], the Middle East [34,50,52], Europe [4,35–40,44,45,47], and the People's Republic of
188 China [3,29,42,43,46,51,53–57]) with a total of 3553 COVID-19 patients developing cardiac complications 188 China [3,29,42,43,46,51,53–57]) with a total of 3553 COVID-19 patients developing cardiac complications and
189 13,225 COVID-19 patients without cardiac complications. Patients who presented with SARS-CoV-2 associated 189 13,225 COVID-19 patients without cardiac complications. Patients who presented with SARS-CoV-2 associated
190 cardiac complications were, on average, 10 years older than in those who did not (Table 2). 190 cardiac complications were, on average, 10 years older than in those who did not (Table 2).
191

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

193
194
195

Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flowchart of 195 study selection.
196

205 207

208

208

210

211

212 212

It is made available under a CC-BY-NC-ND 4.0 International license.

 \Box

10 $10\,$

236

237

238

239

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

12

240 In a pooled analysis, chronic respiratory illness (odds ratio (OR): 1.67, 95% confidence interval (CI)
241 [1.48.1.88]) (Fig. 2), CVD (OR: 3.37, 95% CI [2.57.4.43]) (Fig. 3), hypertension (OR: 2.68, 95% CI 241 [1.48,1.88]) (Fig. 2), CVD (OR: 3.37, 95% CI [2.57,4.43]) (Fig. 3), hypertension (OR: 2.68, 95% CI 242 [2.11.3.41]) (Fig. 4), DM (OR: 1.60, 95% CI [1.31, 1.95]) (Fig. 5), and male sex (OR: 1.31, 95% CI [1.21, 1.42]) 242 [2.11,3.41]) (Fig. 4), DM (OR: 1.60, 95% CI [1.31,1.95]) (Fig. 5), and male sex (OR: 1.31, 95% CI [1.21,1.42])
243 (Fig. 6), were each associated with a higher incidence of SARS-CoV-2 associated cardiac complications.

- 243 (Fig. 6), were each associated with a higher incidence of SARS-CoV-2 associated cardiac complications.
244
-

245

247

248

248

250 **Figure 2:** Forest plot of chronic respiratory illness as a risk factor for cardiac complications in COVID-19 patients. Fixed effect models apply when $I² < 50\%$. 252 patients. Fixed effect models apply when ℓ^2 <50%.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 $^{254}_{255}$ 255

 $\bar{2}5\bar{7}$

 258

260 **Figure 3:** Forest plot of pre-existing cardiovascular disease as a risk factor for cardiac complications in COVID-
261 **19** patients. Random effect models apply when $t^2 > 50\%$. 261 19 patients. Random effect models apply when l^2 > 50%.
262

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

270 **Figure 4:** Forest plot of hypertension as a risk factor for cardiac complications in COVID-19 patients. Random effect models apply when $t^2 > 50\%$. 271 effect models apply when l^2 >50%.
272

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 $^{274}_{275}$ 275

277

 $\frac{1}{278}$

278

280 281

281 Figure 5: Forest plot of diabetes mellitus as a risk factor for cardiac complications in COVID-19 patients.
282 Random effect models apply when $t^2 > 50\%$. 282 Random effect models apply when l^2 > 50%.
283

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

285
286
287

289 As large heterogeneity was detected amongst the total combined study cohort, the cohort was subdivided based
290 on general global region in an attempt to account for this. Cohorts were divided into studies with cohort 290 on general global region in an attempt to account for this. Cohorts were divided into studies with cohorts
291 primarily situated in the U.S.A [32.33.41.48.49], the Middle East [34.50.52]. Europe [4.35-40.44.45.47], an 291 primarily situated in the U.S.A [32,33,41,48,49], the Middle East [34,50,52], Europe [4,35–40,44,45,47], and
292 China [3.29.42.43.46.51.53–57]. 292 China [3,29,42,43,46,51,53–57].
293

293 294 Regionally-pooled sub-analysis of chronic respiratory illness found it to be associated with a higher incidence of
295 SARS-CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.64, 95% CI [1.28, 2.

295 SARS-CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.64, 95% CI [1.28,2.09]) (Fig.
296 7. A). Europe (OR: 1.53, 95% CI [1.28,1.83]) (Fig. 7, C) and China (OR: 1.94, 95% CI [1.49.2.52]) (Fig. 7,

296 7, A), Europe (OR: 1.53, 95% CI [1.28,1.83]) (Fig. 7, C) and China (OR: 1.94, 95% CI [1.49,2.52]) (Fig. 7, D),
297 but not the Middle East (Fig. 7, B). Regional subdivision accounted for the high heterogeneity amongst

297 but not the Middle East (Fig. 7, B). Regional subdivision accounted for the high heterogeneity amongst all but 298 the Middle Eastern cohort.

298 the Middle Eastern cohort.
299

It is made available under a CC-BY-NC-ND 4.0 International license.

300
301
302 Figure 7: Forest plots of chronic respiratory as a risk factor for cardiac complications in COVID-19 patients 302 divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily around the Middle East. C | Studies based primarily in China. 303 primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. 304 Fixed effect models apply when l^2 > 50%. 304 Fixed effect models apply when *and random effects models apply when* $*I*² > 50%$ *.*

305

306 Regionally-pooled sub-analysis of pre-existing CVD found its association with a higher incidence of SARS-
307 CoV-2 associated cardiac complications to be conserved across all cohorts from the U.S.A. (OR: 3.55, 95% CI

307 CoV-2 associated cardiac complications to be conserved across all cohorts from the U.S.A. (OR: 3.55, 95% CI
308 [2.51,5.04]) (Fig. 8, A), the Middle East (OR: 2.40, 95% CI [1.25,4.62]) (Fig. 8, B), Europe (OR: 2.99, 95

308 [2.51,5.04]) (Fig. 8, A), the Middle East (OR: 2.40, 95% CI [1.25,4.62]) (Fig. 8, B), Europe (OR: 2.99, 95% CI 3.89, 95% CI 5.52, 95% CI [3.88,7.85]) (Fig. 8, D), despite regional subdivision

309 [1.90,4.69]) (Fig. 8, C), and China (OR: 5.52, 95% CI [3.88,7.85]) (Fig. 8, D), despite regional subdivision failing to account for high heterogeneity amongst the former three regions.

310 failing to account for high heterogeneity amongst the former three regions.
311

It is made available under a CC-BY-NC-ND 4.0 International license.

 $\frac{312}{313}$
314 Figure 8: Forest plots of pre-existing cardiovascular disease as a risk factor for cardiac complications in COVID-19 patients divided by geographical region. A Studies based primarily in the United States of America. 314 COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America.
315 B | Studies based primarily around the Middle East. C | Studies based primarily in Europe. D | Studies 315 B | Studies based primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based 316 primarily in China. Fixed effect models apply when l^2 >50%. 316 primarily in China. Fixed effect models apply when l^2 <50% and random effects models apply when l^2 >50%.

- 317
318
-

318 319 Regionally-pooled sub-analysis of hypertension found its association with a higher incidence of SARS-CoV-2
320 associated cardiac complications to be similarly conserved across all cohorts from the U.S.A. (OR: 2.23, 95 320 associated cardiac complications to be similarly conserved across all cohorts from the U.S.A. (OR: 2.23, 95%
321 CI [1.22.4.08]) (Fig. 9, A), the Middle East (OR: 2.24, 95% CI [1.70.2.94]) (Fig. 9, B), Europe (OR: 2.38 321 CI [1.22,4.08]) (Fig. 9, A), the Middle East (OR: 2.24, 95% CI [1.70,2.94]) (Fig. 9, B), Europe (OR: 2.38, 95%
322 CI [1.46.3.881) (Fig. 9, C), and China (OR: 3.94, 95% CI [3.10.5.011) (Fig. 9, D), although regional su 322 CI [1.46,3.88]) (Fig. 9, C), and China (OR: 3.94, 95% CI [3.10,5.01]) (Fig. 9, D), although regional subdivision
323 could not account for high heterogeneity amongst the American and European cohorts. 323 could not account for high heterogeneity amongst the American and European cohorts.
324

It is made available under a CC-BY-NC-ND 4.0 International license.

325
326
327 **Figure 9:** Forest plots of hypertension as a risk factor for cardiac complications in COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based primar 327 by geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily
328 around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. 328 around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. Fixed 329 effect models apply when I^2 <50% and random effects models apply when I^2 >50%. 329 effect models apply when l^2 <50% and random effects models apply when l^2 >50%.
330

- 330
331
-

331 332 The association between DM and a higher incidence of SARS-CoV-2 associated cardiac complications was also
333 conserved across all cohorts from the U.S.A. (OR: 1.54, 95% CI [1.32.1.781) (Fig. 10, A), the Middle East (O 333 conserved across all cohorts from the U.S.A. (OR: 1.54, 95% CI [1.32,1.78]) (Fig. 10, A), the Middle East (OR: 334 1.65, 95% CI [1.25,2.19]) (Fig. 10, B). Europe (OR: 1.50, 95% CI [1.07,2.09]) (Fig. 10, C), and China (334 1.65, 95% CI [1.25,2.19]) (Fig. 10, B), Europe (OR: 1.50, 95% CI [1.07,2.09]) (Fig. 10, C), and China (OR:
335 2.04, 95% CI [1.13.3.70]) (Fig. 10, D), despite regional subdivision not accounting for high heterogeneity 335 2.04, 95% CI [1.13,3.70]) (Fig. 10, D), despite regional subdivision not accounting for high heterogeneity amongst the European and Chinese cohorts.

- 336 amongst the European and Chinese cohorts.
337
-

It is made available under a CC-BY-NC-ND 4.0 International license.

338
339
340 **Figure 10:** Forest plots of diabetes mellitus as a risk factor for cardiac complications in COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based 340 divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based
341 orimarily around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in 341 primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China.
342 Fixed effect models apply when l^2 <50% and random effects models apply when l^2 >50%. $\frac{342}{343}$ Fixed effect models apply when $\frac{12}{50\%}$ and random effects models apply when $\frac{12}{50\%}$.

- 343
344
-
- 345 345 Finally, regionally-pooled sub-analysis of male sex found it to be associated with a higher incidence of SARS-
346 CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.55, 95% CI [1.03.2.33]) (Fig.
- 346 CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.55, 95% CI [1.03,2.33]) (Fig. 11, A),
347 and Europe (OR: 1.40, 95% CI [1.23,1.59]) (Fig. 11, C), but not the Middle East (Fig. 11, B) or China (
- 347 and Europe (OR: 1.40, 95% CI [1.23,1.59]) (Fig. 11, C), but not the Middle East (Fig. 11, B) or China (Fig. 11, 348 D). Regional subdivision accounted for the high heterogeneity amongst all but the American cohort.
- 348 D). Regional subdivision accounted for the high heterogeneity amongst all but the American cohort.
349
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

350
351
352 **Figure 11:** Forest plots of male sex as a risk factor for cardiac complications in COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily 352 geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily
353 around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. Fix 353 around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. Fixed 354 effect models apply when t^2 <50% and random effects models apply when t^2 >50%. 354 effect models apply when l^2 <50% and random effects models apply when l^2 >50%.
355

- ---
356
- 356
-
-
-
- 360
- 361
- 362
-
-

It is made available under a CC-BY-NC-ND 4.0 International license.

³⁶⁵**DISCUSSION**

367 367 Our meta-analysis shows that older age, male sex, and pre-existing chronic respiratory disease, CVD,
368 hypertension and DM are all risk factors for the development of cardiac complications associated with SARS-368 hypertension and DM are all risk factors for the development of cardiac complications associated with SARS-
369 CoV-2 infection. At present the reasons for each of these association are unclear: each is a respiratory r 369 CoV-2 infection. At present the reasons for each of these association are unclear; each is a respiratory risk factor
370 and thus might cause an indirect cardiac effect, however it could equally be the case that they e 370 and thus might cause an indirect cardiac effect, however it could equally be the case that they exert their own
371 direct catalytic effect on cardiac complications. 371 direct catalytic effect on cardiac complications.
372

372 373 Our analysis identified a significant association between pre-existing CVD and the risk of SARS-CoV-2
374 associated cardiac complications, which was conserved across global geographical regions. This is consistent 374 associated cardiac complications, which was conserved across global geographical regions. This is consistent
375 with previous observations that 30% of patients with SARS-CoV-2 cardiac injury had a history of coronary 375 with previous observations that 30% of patients with SARS-CoV-2 cardiac injury had a history of coronary
376 heart disease 13.291. The reason for this association remains unclear. These data may be the result of pre-376 heart disease [3,29]. The reason for this association remains unclear. These data may be the result of pre-
377 existing CVD leading to an altered immune response excessive cytokine release [5] endothelial dysfunction 377 existing CVD leading to an altered immune response, excessive cytokine release [5], endothelial dysfunction,
378 increased procoagulant blood activity, rupturing of coronary atherosclerotic plagues [73], and the format 378 increased procoagulant blood activity, rupturing of coronary atherosclerotic plaques [73], and the formation of an occlusive thrombi [74]. However, further investigations are required to validate this hypothesis. 379 an occlusive thrombi [74].However, further investigations are required to validate this hypothesis.
380

381 381 The meta-analysis performed herein also found that chronic respiratory illness significantly increased the
382 incidence of SARS-CoV-2 associated cardiac complications. It is possible that these data reflect the establ 382 incidence of SARS-CoV-2 associated cardiac complications. It is possible that these data reflect the established
383 indirect association between severe respiratory disease and subsequent acute cardiovascular event Ind 383 indirect association between severe respiratory disease and subsequent acute cardiovascular event Indeed,
384 COVID-19 patients with pneumonia and acute respiratory distress syndrome (ARDS) display acute right 384 COVID-19 patients with pneumonia and acute respiratory distress syndrome (ARDS) display acute right
385 ventricular hypertrophy despite an absence of pulmonary embolism or severe pulmonary hypertension [87]. 385 ventricular hypertrophy despite an absence of pulmonary embolism or severe pulmonary hypertension [87].
386 However, chronic lung disease has not been consistently associated with SARS-CoV-2 ARDS and hypoxemia 386 However, chronic lung disease has not been consistently associated with SARS-CoV-2 ARDS and hypoxemia
387 [88], and thus this is unlikely to be the sole explanation for the increased risk of cardiac complications in 387 [88], and thus this is unlikely to be the sole explanation for the increased risk of cardiac complications in
388 patients with chronic respiratory illness in the present analysis. SARS-CoV-2 associated cardiac complic 388 patients with chronic respiratory illness in the present analysis. SARS-CoV-2 associated cardiac complications 389

390 390 The association between underlying DM and cardiac complications from SARS-CoV-2 may be attributable to a
391 multitude of other effects induced by abnormal circulating substrates, including hyperglycaemia, and/or the c 391 multitude of other effects induced by abnormal circulating substrates, including hyperglycaemia, and/or the co-
392 existence and complex interactions with other, even subclinical, conditions in this patient group [91] 392 existence and complex interactions with other, even subclinical, conditions in this patient group [91]. In
393 response to changes in substrate availability, for example, the diabetic heart becomes increasingly depende 393 response to changes in substrate availability, for example, the diabetic heart becomes increasingly dependent on
394 fatty acids as a fuel source, which decreases work efficiency, and dysregulates responses to hypoxia 394 fatty acids as a fuel source, which decreases work efficiency, and dysregulates responses to hypoxia [92]. These
395 metabolic changes may predispose individuals with DM to an increased risk of ischemic cardiac injury 395 metabolic changes may predispose individuals with DM to an increased risk of ischemic cardiac injury upon
396 SARS-CoV-2 infection. The contribution of underlying DM to the risk of SARS-CoV-2 associated cardiac 396 SARS-CoV-2 infection. The contribution of underlying DM to the risk of SARS-CoV-2 associated cardiac
397 complications, however, depends largely on the duration of pre-existing disease [93]. 397 complications, however, depends largely on the duration of pre-existing disease [93].
398

-
- 398

400 400 There are several limitations in our review. Firstly, the limited number of studies that met the pre-defined
401 selection criteria disallowed correction for other variables that may confound these results. For example selection criteria disallowed correction for other variables that may confound these results. For example, it is
402 spossible that our observations were confounded by the strong effect that age has on cardiovascular healt possible that our observations were confounded by the strong effect that age has on cardiovascular health. Thus,
403 it is not possible to conclude if people with these pre-existing conditions are just more susceptible to 403 it is not possible to conclude if people with these pre-existing conditions are just more susceptible to severe
404 COVID-19 and thus the heart complications associated with this increased severity, or if there is inde ⁴⁰⁴COVID-19 and thus the heart complications associated with this increased severity, or if there is indeed a

It is made available under a CC-BY-NC-ND 4.0 International license.

405 cardiac-specific effect occurring. Similarly, we cannot exclude the possibility that the associations observed
406 herein are due, at least in part, to treatments for severe COVID-19 that may damage the heart. Indeed, 406 herein are due, at least in part, to treatments for severe COVID-19 that may damage the heart. Indeed, the
407 experimental therapeutic hydroxychloroquine has been associated with OT interval prolongation, 407 experimental therapeutic hydroxychloroquine has been associated with QT interval prolongation,
408 cardiomyopathy and heart failure [8–10]. This is likewise the case for treatments for underlying conditions, such 408 cardiomyopathy and heart failure [8–10]. This is likewise the case for treatments for underlying conditions, such
409 as ACE inhibitors and ARBs which, while not known to damage the heart, may interfere with how the im 409 as ACE inhibitors and ARBs which, while not known to damage the heart, may interfere with how the immune
410 system targets the virus [78]. Information regarding which, if any, therapeutics used in these cohorts of pat 410 system targets the virus [78]. Information regarding which, if any, therapeutics used in these cohorts of patients 411 was not consistently available. We anticipate that as more data on the cardiac complications become 411 was not consistently available. We anticipate that as more data on the cardiac complications become available it
412 will be possible for future analyses to correct for these and other confounders: however, it would al will be possible for future analyses to correct for these and other confounders; however, it would also be
413 worthwhile testing the effects of each these pre-existing chronic conditions in one of the recently developed 413 worthwhile testing the effects of each these pre-existing chronic conditions in one of the recently developed murine models of SARS-CoV-2. 414 murine models of SARS-CoV-2.
415

415 416 Despite the above limitations, these data have important implications for patient care. Patients with one or more
417 underlying medical conditions should be closely monitored for both severe respiratory and extra-resp 417 underlying medical conditions should be closely monitored for both severe respiratory and extra-respiratory 418 COVID-19 complications. Furthermore, the exploratory use of medications that are independently associated 418 COVID-19 complications. Furthermore, the exploratory use of medications that are independently associated
419 with cardiac complications should be considered with caution in these patient groups and perhaps bypassed in with cardiac complications should be considered with caution in these patient groups and perhaps bypassed in 420 favour of lower-risk treatment options. There is thus a clear need for a multidisciplinary, collaborative tea 420 favour of lower-risk treatment options. There is thus a clear need for a multidisciplinary, collaborative team to
421 manage the complexity of COVID-19 illness observed in patients with one or more underlying chronic d 421 manage the complexity of COVID-19 illness observed in patients with one or more underlying chronic disease.
422

422 ⁴²³**RESOURCE AVAILABILITY**

425 **Lead contact:** Further information and requests for resources should be directed to and will be fulfilled by the 426 Lead Contact. Dr. Kirsty Short (k.short@uq.edu.au). 426 Lead Contact, Dr. Kirsty Short (**k.short@uq.edu.au**).
427

428 ⁴²⁸**Materials availability:** This study did not generate new unique reagents.

429 **Data and code availability:** All data relevant to this study has been included in the manuscript. Data
431 contributed by Xu et al., 2020³¹, Ma et al., 2020³², and Arentz et al., 2020³⁵, may be obtained by contactin 431 contributed by Xu et al., 2020^{31} , Ma et al., 2020^{32} , and Arentz et al., 2020^{35} , may be obtained by contacting 432 authors of each respective study. Data retrieved from remaining studies are published and p 432 authors of each respective study. Data retrieved from remaining studies are published and publicly available. R
433 version 4.0.0 software was used to analyse sex distribution as well as pre-existing chronic disease an 433 version 4·0·0 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac 434 outcomes through meta analysis. The datasets/code supporting the current study have not been deposi 434 outcomes through meta \exists analysis. The datasets/code supporting the current study have not been deposited in a
435 oublic repository but are available from the corresponding author on request. 435 public repository but are available from the corresponding author on request.
436

-
- 437
- 438
- 438
- 440
- 440
- 441
- 442 443

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

24

444
445

⁴⁴⁵**DECLARATIONS**

447 Acknowledgements: We want express our gratitude to the CAPACITY-COVID collaborative
448 consortium for their data contribution 448 consortium for their data contribution:
449 Admiraal de Ruyter Hospital, Goes, the Netherlands: van Kesteren HAM A150 Albert Schweitzer Hospital, Dordrecht, the Netherlands: van de Watering DJ

Amphia Hospital, Breda, the Netherlands: Schaap J, Alings AMW

452 Amstelland Hospital, Amstelveen, the Netherlands: Asselbergs-Koning AMH

4 Amphia Hospital, Breda, the Netherlands: Schaap J, Alings AMW Amstelland Hospital, Amstelveen, the Netherlands: Asselbergs-Koning AMH Amsterdam University Medical Center, Amsterdam, the Netherlands: Pinto Y, Tjong FVY Antonius Hospital, Sneek, the Netherlands: de Vries JK Antwerp University Hospital, Antwerp, Belgium: van Craenenbroeck EM, Kwakkel - van Erp HM, van lerssel S AZ Maria Middelares, Gent, Belgium: de Sutter J Barts Health NHS Trust, London, United Kingdom: Saxena M Beatrix Hospital, Gorinchem, the Netherlands: Westendorp PHM 459 Bernhoven Hospital, Uden, the Netherlands: van de Wal RMA
 460 Bravis Hospital, Roosendaal, the Netherlands: Dorman HGR, v 460 Bravis Hospital, Roosendaal, the Netherlands: Dorman HGR, van Boxem AJM
461 Catharina Hospital, Eindhoven, the Netherlands: Tio RA
462 CHU UCL Namur – Site Godinne, Yvoir, Belgium: Gabriel LG
463 Deventer Hospital, Dev Catharina Hospital, Eindhoven, the Netherlands: Tio RA CHU UCL Namur - Site Godinne, Yvoir, Belgium: Gabriel LG Deventer Hospital, Deventer, the Netherlands: Badings EA Diakonessenhuis, Utrecht, the Netherlands: van Ofwegen-Hanekamp CEE 465 Dijklander Hospital, Hoorn, the Netherlands: Wierda E
466 Dutch Network for Cardiovascular Research (WCN): Sc
467 Elizabeth-TweeSteden Hospital, Tilburg, the Netherlan
468 E.M.M.S Hospital, Nazareth, Israel: Hellou EH Dutch Network for Cardiovascular Research (WCN): Schut A Elizabeth TweeSteden Hospital, Tilburg, the Netherlands: Monraats PS 468 E.M.M.S Hospital, Nazareth, Israel: Hellou EH
469 Erasmus University Medical Center, Rotterda
4771 Fransiscus Viietland, Schiedan, the Netherland
472 Gelre Hospitals, Apelonon, the Netherlands
473 Gelre Hospitals, Zutp Erasmus University Medical Center, Rotterdam, the Netherlands: den Uil CA, Jewbali LS Fransiscus Gasthuis, Rotterdam, the Netherlands: Nierop PR Fransiscus Vlietland, Schiedam, the Netherlands: van der Linden MMJM Gelre Hospitals, Apeldoorn, the Netherlands: Groenemeijer BE Gelre Hospitals, Zutphen, the Netherlands: Al-Windy NYY Groene Hart Hospital, Gouda, the Netherlands: van Hessen MWJ Hart Hospital, Gouda, Salemce, Manag, Inc. Netherlands: van der Heijden DJ
176 Hospital do Espirito Santo, Évora, Portugal: Ribeiro MIA
177 Hospital Group Twente, Almelo, the Netherlands: Linssen GCM
178 Hospital Prof. Dou Hospital do Espirito Santo, Évora, Portugal: Ribeiro MIA Hospital Group Twente, Almelo, the Netherlands: Linssen GCM Hospital Prof. Doutor Fernando Fonesca, Amadora, Portugal: Ferreira JB Imperial College Healthcare NHS Trust, London, United Kingdom: Prasad S I.M. Sechenov First Moscow State Medical University, Moscow, Russia: Kopylov Ph. Yu., Blagova OV Ikazia Hospital, Rotterdam, the Netherlands: Emans ME Incliva Research Institute, University of Valencia, Valencia, Spain: Redón J, Forner MJ Isala, Zwolle, the Netherlands: Hermanides RS Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands: Haerkens-Arends HE Jessa Hospital, Hasselt, the Netherlands: Timmermans PJr, Messiaen P Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands: van Smeden M 1886 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands: Van Smeden M
487 – King Fahd Hospital of the University, Khobar, Saudi Arabia: Al-Ali AK, Al-Muhanna FA, Al-Rubai 487 King Fahd Hospital of the University, Khobar, Saudi Arabia: Al-Ali AK, Al-Muhanna FA, Al-Rubaish AM, Almubarak YA, Alnafie AN, 488 Alshahrani M, Alshehri A

488 Alshahrani M, Alshehri A

LangeLand Hospital, Zoetermeer, the Netherlands: van der Meer P

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom: Kearney

Leeuwarden Medical Center, Le Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom: Kearney M Leeuwarden Medical Center, Leeuwarden, the Netherlands: van den Brink FS Leiden University Medical Center, Leiden, the Netherlands: Siebelink HJ Maasstad Hospital, Rotterdam, the Netherlands: Smits PC Maastricht University Medical Center, Maastricht, the Netherlands: Heymans SRB Manchester University NHS Foundation Trust, Manchester, United Kingdom: Buch M Martini Hospital, Groningen, the Netherlands: Tieleman RG, Reidinga AC Meander Medical Center, Amersfoort, the Netherlands: Mosterd A Medisch Spectrum Twente, Enschede, the Netherlands: Meijs MFL, Delsing CE, van Veen HPAA

1998 Morthumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom: Aujayeb A

501 Morthumbria Healthcare NHS Foundation Netherlands Heart Institute, Utrecht, the Netherlands: Hermans-van Ast W, Iperen EPA Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom: Aujayeb A One Day Surgery Hospital, Cairo, Egypt: Salah R Queen Elizabeth University Hospital, Glasgow, United Kingdom: Touyz R Rijnstate Hospital, Arnhem, the Netherlands: Seelig J Rode Kruis Hospital, Beverwijk, the Netherlands: Westendorp ICD, Veldhuis LI Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom: Prasad S Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom: Shore AC Royal Free London NHS Foundation Trust, London, United Kingdom: Captur G Salford Royal NHS Foundation Trust, Salford, United Kingdom: Dark P San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy: Montagna LM, Bianco MB, Mazzilli SGM Saxenburgh Medical Center, Hardenberg, the Netherlands: Kaplan R, Drost JT 5420 Saxenburgh Medical Center, Hardenberg, the Netherlands: Kaplan R, Drost JT
511 Slingeland Hospital, Doetinchem, the Netherlands: Schellings DAAM 511 Slingeland Hospital, Doetinchem, the Netherlands: Schellings DAAM

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

-
-
- SSR Val Rosay, Saint-Didier-au-Mont-d'Or, France: Charlotte NC
- St. Antonius Hospital, Nieuwegein, the Netherlands: ten Berg JM
- St. Jansdal, Harderwijk, the Netherlands: van der Zee PM
- Tehran Heart Center, Tehran, Iran: Shafiee A, Hedayat B, Poorhosseini H, Saneei E The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom: Zaman A
- Treant Zorggroep, Hoogeveen, the Netherlands: Anthonio RL
- University College London Hospitals NHS Foundation Trust, London, United Kingdom: Williams B, Patel R, Bell R
- University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom: Caputo M
- University Hospital Brussels, Brussels, Belgium: Weytjens C
- University Hospital Complex of Granada, Granada, Spain: Macías-Ruiz R
- University Hospital of Geneva, Geneva, Switzerland: Tessitore E
- University Hospitals of Leicester NHS Trust, Leicester, United Kingdom: McCann GP
- University Medical Center Groningen, Groningen, the Netherlands: van Gilst WH
- 512 Southern Health and Social Care Trust, Portadown, United Kingdom: Moriarty A

513 Spaarne Gasthuis, Haarlem, the Netherlands: Kuijper AFM

514 SSR Val Rosay, Saint-Dider-au-Mont-d'Or, France: Charlotte NC

515 St. Anto University Medical Center Utrecht, Utrecht, the Netherlands: Asselbergs FW, van der Harst P, Linschoten M
- Van Weel-Bethesda Hospital, Dirksland, the Netherlands: Wu KW
- Zaans Medical Center, Zaandam, the Netherlands: Verschure DO
- $\frac{5}{5}\overline{30}$ Zaans Medical Center, Zaandam, the Netherlands: Verschure DO $\overline{530}$ 530 Zuyderland Medical Center, Heerlen, the Netherlands: Kietselaer BLJH 530
531
- 532 Author contributions: Idea and study design: KRS, LAG; Data collection and analysis: JES, YZ, GX, WM, 533 HS, K-LM, C-FC, L-XK, K-OW, JL, MA, KRS; Writing the article: JES, KRS; Draft revision: JES, GX, WM,
- 533 HS, K-LM, C-FC, L-XK, K-QW, JL, MA, KRS; Writing the article: JES, KRS; Draft revision: JES, GX, WM, 534 HS, K-LM, C-FC, L-XK, K-OW, JL, MA, MR, LAG, KRS; All authors have read the manuscript and have
- 534 HS, K-LM, C-FC, L-XK, K-QW, JL, MA, MR, LAG, KRS; All authors have read the manuscript and have approved this submission.
- approved this submission.
- **Declaration of interests:** The authors declare no conflict of interest. The funders had no role in the design of the study: in the collection, analyses, or interpretation of data: in the writing of the manuscript, or in t
- 537 the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- to publish the results.
- ⁵³⁹**Funding:** KRS was supported by the Australian Research Council [DE180100512]. Collection of data
- 540 contributed by Xu et al. was supported by the Guangzhou Health Research Project, the Guangzhou Health 541 Committee (NO.20191A010014).
- Committee (NO.20191A010014).
- 542 **Ethics approval and consent to participate:** The meta-analysis portion of this project was reviewed by the 543 Human Ethics Research Office. The University of Queensland (CRICOS provider number: 00025B: application
- 543 Human Ethics Research Office, The University of Queensland (CRICOS provider number: 00025B; application
544 number: 2020001352) and deemed to be exempt from ethics review under the National Statement on Ethical
- 544 number: 2020001352) and deemed to be exempt from ethics review under the National Statement on Ethical
545 Conduct in Human Research (National Statement 85.1.22).
- Conduct in Human Research (National Statement §5.1.22).

546 REFERENCES
547

-
- 548 548 1. Clerkin KJ, Fried JA, Raikhelkar J et al. COVID-19 and cardiovascular disease. Circulation.
549 2020:141:1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941. 549 2020;141:1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941.
550 2. Huang C. Wang Y. Li X et al. Clinical features of patients infected wi
- 550 2. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
551 China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.
- 551 China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.
552 3. Guo T, Fan Y, Chen M et al. Cardiovascular implications of fatal outco 552 3. Guo T, Fan Y, Chen M et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; doi:10.1001/jamacardio.2020.1017. 553 disease 2019 (COVID-19). JAMA Cardiol. 2020; doi:10.1001/jamacardio.2020.1017.
554 4. Sala S, Peretto G, Gramegna M et al. Acute myocarditis presenting as a reverse Tako
- 554 4. Sala S, Peretto G, Gramegna M et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a
555 patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-1862. 555 patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-1862.
556 doi:10.1093/eurhearti/ehaa286. 556 doi:10.1093/eurheartj/ehaa286.
557 5. Zheng Y, Ma Y, Zhang J, Xie Y
- 557 5. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-
558 260. doi:10.1038/s41569-020-0360-5. 558 260. doi:10.1038/s41569-020-0360-5.
559 6. Inciardi RM. Lip L. Zaccone G et a
- 559 6. Inciardi RM, Lip L, Zaccone G et al. Cardiac involvement in a patient with coronavirus disease 2019
560 (COVID-19). JAMA Cardiol. 2002: doi:10.1001/jamacardio. 2020.1096. ⁵⁶⁰(COVID-19). JAMA Cardiol. 2002; doi:10.1001/jamacardio.2020.1096.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 561 7. Edelson DP, Sasson C, Chan PS, et al. Interim guidance for basic and advanced life support in adults,
562 children, and neonates with suspected or confirmed COVID-19: from the Emergency Cardiovascular Care 563 Committee and Get With the Guidelines® -Resuscitation Adult and Pediatric Task Forces of the American 564 Heart Association in collaboration with the American Academy of Pediatrics, American Association for ⁵⁶⁴Heart Association in collaboration with the American Academy of Pediatrics, American Association for ⁵⁶⁵Respiratory Care, American College of Emergency Physicians, the Society of Critical Care 566 Anesthesiologists: supporting organisations: American Association of Critical Care Nurses and National 567 EMS Physicians. Circulation. 2020; doi:10.1161/CIRCULATIONAHA.120.047463. 567 EMS Physicians. Circulation. 2020; doi:10.1161/CIRCULATIONAHA.120.047463.
568 8. Page RL, 2nd. O'Brvant CL, Cheng D et al. Drugs that may cause or exacerbate he
- 568 8. Page RL, 2nd, O'Bryant CL, Cheng D et al. Drugs that may cause or exacerbate heart failure: a scientific 569 statement from the American Heart Association. Circulation. 2016:134(6):e32-69. 569 statement from the American Heart Association. Circulation. 2016;134(6):e32-69.
570 doi:10.1161/cir.000000000000426. 570 doi:10.1161/cir.0000000000000426.
571 – Guzik TI Mobiddin SA Dimarco A
- 571 9. Guzik TJ, Mohiddin SA, Dimarco A et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; doi:10.1093/cvr/cvaa106. 572 ssessment, diagnosis, and treatment options. Cardiovasc Res. 2020; doi:10.1093/cvr/cvaa106.
573 10. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y-M. Cardiac complications attributed to chloroquine
- 573 10. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y-M. Cardiac complications attributed to chloroquine
574 and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018:41(10):919-931. 574 and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919-931.
575 doi:10.1007/s40264-018-0689-4. 575 doi:10.1007/s40264-018-0689-4.
576 11. Castagné B, Viprey M, Martin
- 576 11. Castagné B, Viprey M, Martin J, Schott A-M, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS ONE. 2019; 577 tocilizumab: a systematic review and network meta-analysis. PLoS ONE. 2019;
578 doi:10.1371/journal.pone.0220178. ⁵⁷⁸doi:10.1371/journal.pone.0220178.
- 579 12. Corrales-Medina VF, Alvarez KN, Weissfeld LA et al. Association between hospitalization for pneumonia
580 12. and subsequent risk of cardiovascular disease. JAMA. 2015:313(3):264-274. doi:10.1001/jama.2014.18229. 580 and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-274. doi:10.1001/jama.2014.18229.
581 13 Wang D. Hu. B. Hu. C. et. al. Clinical characteristics, of. 138. hospitalised, patients, with. 2019. novel
- 581 13. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
583 doi:10.1001/jama.2020.1585. 582 coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
583 doi:10.1001/jama.2020.1585. 583 doi:10.1001/jama.2020.1585.
584 14 Giustino G. Croft I. B. Stefa
- 584 14. Giustino G., Croft L.B., Stefanini G.G. Characterization of myocardial injury in patients with COVID-19. J
585 Am Coll Cardiol. 2020:76:2043–2055. 585 Am Coll Cardiol. 2020;76:2043–2055.
586 15. Lippi G, Henry BM. Chronic obstruct
- 586 15. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 587 2019 (COVID-19). Respir Med. 2020; doi:10.1016/j.rmed. 2020.105941. 587 2019 (COVID-19). Respir Med. 2020; doi:10.1016/j.rmed.2020.105941.
588 16. Li B. Yang J. Zhao F et al. Prevalence and impact of cardiovascular m
- 588 16. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020:109:521-538. doi:10.1007/s00392-020-01626-9.
- 589 China. Clin Res Cardiol. 2020;109:521-538. doi:10.1007/s00392-020-01626-9.
590 17. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adu 590 17. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19
591 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-591 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-
592 6736(20)30566-3. 592 6736(20)30566-3.
593 18. Yang J, Zheng Y,
- 593 18. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected with SARS-
594 CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. 594 CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
595 doi:10.1016/j.iiid.2020.03.017. 595 doi:10.1016/j.ijid.2020.03.017.
596 19. Chen N, Zhou M, Dong X et
- 596 19. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
597 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
598 doi:10.1016/ ⁵⁹⁷coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. 598 doi:10.1016/S0140-6736(20)30211-7.
599 20. Epidemiology Working Group for N
- 599 20. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and 600 Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease 600 Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease 601 (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-151. 601 (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-151.
602 doi:10.3760/cma.j.issn.0254-6450.2020.02.003. 602 doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
603 21. Yang X, Yu Y, Xu J et al. Clinical course a
- ⁶⁰³21. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 604 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. 605 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5. 605 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5.
606 22. Wu Z, McGoogan JM. Characteristics of and importa
- ⁶⁰⁶22. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 607 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease 608 control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648. 608 Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
609 23. Targher G, Mantovani A, Wang X-B et al. Patients with diabetes are at higher risk for
- 609 23. Targher G, Mantovani A, Wang X-B et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020; doi:10.1016/j.diabet. 2020.05.001 610 COVID-19. Diabetes Metab. 2020; doi:10.1016/j.diabet.2020.05.001
611 24. Fang L. Karakiulakis G. Roth M. Are patients with hypertension and
- 611 24. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8. 612 COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8.
613 25. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome a
- 613 25. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in 614 patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 614 patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;
615 doi:10.1001/jamainternmed.2020.0994. 615 doi:10.1001/jamainternmed.2020.0994.
616 26. Ruan O. Yang K. Wang W. Jiang L. So
- 616 26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an 617 analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848. ⁶¹⁷analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

708 63. Wang J, Xu H, Yang X et al. Cardiac complications associated with the influenza viruses A subtype H7N9 ⁷⁰⁸63. Wang J, Xu H, Yang X et al. Cardiac complications associated with the influenza viruses A subtype H7N9 709 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis. 2017;21(1):12-18.
710 oi:10.1016/i.biid.2016.10.005. 710 doi:10.1016/j.bjid.2016.10.005.
711 64. Estabragh ZR, Mamas A. The

- 711 64. Estabragh ZR, Mamas A. The cardiovascular manifestations of influenza: a systematic review. Int J
712 Cardiol. 2013;167(6):2397-2403. doi:10.1016/j.ijcard.2013.01.274. 712 Cardiol. 2013;167(6):2397-2403. doi:10.1016/j.ijcard.2013.01.274.
713 65. Ito T. Akamatsu K. Ukimura A et al. The prevalence and findi
- 713 65. Ito T, Akamatsu K, Ukimura A et al. The prevalence and findings of subclinical influenza-associated cardiac abnormalities among Japanese patients. Intern Med. 2018;57(13):1819-1826. 714 cardiac abnormalities among Japanese patients. Intern Med. 2018;57(13):1819-1826.
715 doi:10.2169/internalmedicine.0316-17. 715 doi:10.2169/internalmedicine.0316-17.
716 66 Chacko B Peter IV Pichamutha K et
- 716 66. Chacko B, Peter JV, Pichamutha K et al. Cardiac manifestations in patients with pandemic (H1N1) 2009
717 virus infection needing intensive care. J Crit Care. 2012:27(1):e1-106. doi:10.1016/i.jcrc.2011.05.016. 717 virus infection needing intensive care. J Crit Care. 2012;27(1):e1-106. doi:10.1016/j.jcrc.2011.05.016.
718 67. Wells GA. Shea B. O'Connell D et al. 2019. The Newcastle-Ottawa Scale (NOS) for assessing the qu
- 718 67. Wells GA, Shea B, O'Connell D et al. 2019. The Newcastle-Ottawa Scale (NOS) for assessing the quality studies in the originally studies in the meta-analyses. 719 of nonrandomised studies in meta-analyses.
720 http://www.ohri.ca/programs/clinical epidemiology/oxford.asp. Accessed 27 July 2020.
- 720 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 27 July 2020.
721 68 Moher D. Liberati A. Tetzlaff L. Altman DG. The PRISMA Group, Preferred reporting i ⁷²¹68. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic 722 reviews and meta-analysis: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
723 doi:10.1371/journal.pmed.1000097. 723 doi:10.1371/journal.pmed.1000097.
724 69. Stroup AF. Berlin JA. Morton SC et
- ⁷²⁴69. Stroup AF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal 725 for reporting. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008.
726 70. Nehring SM., Goval A., Bansal P., Patel B.C. (2020). C Reactive Protein (CRP
- 726 70. Nehring SM., Goyal A., Bansal P., Patel B.C. (2020). C Reactive Protein (CRP) [Updated 2020 Jun 5]. In:
727 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: 728 https://www.ncbi.nlm.nih.gov/books/NBK441843/ 728 https://www.ncbi.nlm.nih.gov/books/NBK441843/.
729 71. Ekelund S. Manfred K. Choosing cut-offs
- 729 71. Ekelund S, Manfred K. Choosing cut-offs for NT-proBNP. 2011. https://acutecaretesting.org/-
730 /media/acutecaretesting/files/pdf/choosing-cutoffs-for-ntprobnp.pdf 730 *media/acutecaretesting/files/pdf/choosing-cutoffs-for-ntprobnp.pdf*
731 72. Lindsey J.B., Kennedy K.F., Stolker J.M., Gilchrist I.C, Mukherjee I
- 731 72. Lindsey J.B., Kennedy K.F., Stolker J.M., Gilchrist I.C, Mukherjee D., Marso S.P., *et al.* (2011). Prognostic implications of Creatine Kinase-MB elevation after percutaneous coronary intervention. *Circ Cardiovasc* 732 implications of Creatine Kinase-MB elevation after percutaneous coronary intervention. *Circ Cardiovasc* **733** *Interv.* 4. 474-480. ⁷³³*Interv*, 4, 474-480.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 734 73. Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. Systemic infections cause exaggerated 735 local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections o 735 local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on
736 acute coronary syndromes. Tex Heart Inst J. 2007:34(1):11-18. PMID:17420787. 736 acute coronary syndromes. Tex Heart Inst J. 2007;34(1):11-18. PMID:17420787.
737 74. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumoi
- 737 74. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013;381(9865):496-505. doi:10.1016/S0140-6736(12)61266-5.
- 739 75. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of 739 75. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of 740 angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II 740 angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II
741 receptors Hypertension 2004:43(5):970–976 doi:10.1161/01.HYP.0000124667.34652.1a. 741 receptors. Hypertension. 2004;43(5):970–976. doi:10.1161/01.HYP.0000124667.34652.1a.
742 76. Wang J, He W, Guo L et al. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac
- 742 76. Wang J, He W, Guo L et al. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Molec Med Rep. 2017;16(2):1973-1981. 744 doi:10.3892/mmr.2017.6848. ⁷⁴⁴doi:10.3892/mmr.2017.6848.
- 745 77. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and 746 angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 746 angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation.
747 2005;111(20):2605–2610. doi:10.1161/circulationaha.104.510461.
- 747 2005;111(20):2605–2610. doi:10.1161/circulationaha.104.510461.
748 78. Gheblawia M. Wang K. Viveirosa A et al. Angiotensin converting enzyme 2: SARSCoV-2 receptor and 74878. Gheblawia M, Wang K, Viveirosa A et al. Angiotensin converting enzyme 2: SARSCoV-2 receptor and 749 regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ 749 regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ
750 Res. 2020: doi:10.1161/CIRCRESAHA.120.317015. 750 Res. 2020; doi:10.1161/CIRCRESAHA.120.317015.
751 79. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the
- 75179. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313□1326. doi:10.1161/CIRCRESAHA.116.307708.
- 52 system in heart failure. Circ Res. 2016;118(8):1313□1326. doi:10.1161/CIRCRESAHA.116.307708.
753 80. Marchiano S, Hsiang T-Y, Higashi T, et al. SARS-CoV-2 infects human pluripotent stem cell-d 753 80. Marchiano S, Hsiang T-Y, Higashi T, et al. SARS-CoV-2 infects human pluripotent stem cell-derived
754 cardiomyocytes, impairing electrical and mechanical function. *bioRxiv*. 2020; doi: 2754 cardiomyocytes, impairing electrical and mechanical function. *bioRxiv*. 2020; doi:

2020; 10.1101/2020.08.30.274464.

2756 81 Lindner D Fitzek A Brauninger H et al Association of cardiac infection with SARS-CoV-2 in
- 756 81. Lindner D, Fitzek A, Brauninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed 757 COVID-19 autopsy cases. JAMA Cardiol. 2020: doi: 10.1001/jamacardio. 2020.3551. ⁷⁵⁷COVID-19 autopsy cases. JAMA Cardiol. 2020; doi: 10.1001/jamacardio.2020.3551.
- 758 82. Han MLK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation.
759 2007:116(25):2992-3005. doi:10.1161/CIRCULATIONAHA.106.685206. ⁷⁵⁹2007;116(25);2992-3005. doi:10.1161/CIRCULATIONAHA.106.685206.
- 760 83. Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3(1):5-19. doi:10.4103/2045-8932.109910. 761 patient phenotypes. Pulm Circ. 2013;3(1):5-19. doi:10.4103/2045-8932.109910.
762 84. Barnes M. Heywood AE, Mahimbo A. Rahman B. Newall AT, Macintyre CR.
- 762 84. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction
763 and influenza: a meta-analysis of case-control studies. Heart. 2015:101(21):1738-1747. 763 and influenza: a meta-analysis of case-control studies. Heart. 2015;101(21):1738-1747.
764 doi:10.1136/heartin1-2015-307691. 764 doi:10.1136/heartjnl-2015-307691.
765 85. Carter P. Lagan J. Fortune C et al. *A*
- 765 85. Carter P, Lagan J, Fortune C et al. Association of cardiovascular disease with respiratory disease. J Am Coll
766 Cardiol. 2019:73(17):2166-2177. doi:10.1016/j.jacc.2018.11.063. 766 Cardiol. 2019;73(17):2166-2177. doi:10.1016/j.jacc.2018.11.063.
767 86. Ingebrigsten TS, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Coronary heart disease and heart failure
- 767 86. Ingebrigsten TS, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Coronary heart disease and heart failure
768 https://www.maro.com/2010/2010/2010/2010/2010/2010 768 in asthma, COPD and asthma-COPD overlap. BMJ Open Resp Res. 2020;7:e000470. doi:10.1136/bmjresp-2019-000470.
1970 87. Martinez-Mateo V, Fernandez-Anguita MJ, Paule A. Electrocardiographic signs of acute right ventricular
- 770 87. Martinez-Mateo V, Fernandez-Anguita MJ, Paule A. Electrocardiographic signs of acute right ventricular
771 hypertrophy in patients with COVID-19 pneumonia: A clinical case series. Electrocardiology. 771 bypertrophy in patients with COVID-19 pneumonia: A clinical case series. Electrocardiology.
772 2020:62:100–102. 772 2020;62:100–102.
773 88. Halpin DMG. Fan
- 773 88. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet. 2020: doi:10.1016/S2213-2600(20)30167-3. 774 affect the risk of SARS-CoV-2 infection? Lancet. 2020; doi:10.1016/S2213-2600(20)30167-3.
775 89. Bermejo-Martin JF, Martin-Fernandez M, Lopez-Mestanza C, Duque P, Almansa R. Share
- ⁷⁷⁵89. Bermejo-Martin JF, Martin-Fernandez M, Lopez-Mestanza C, Duque P, Almansa R. Shared features of 776 endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin 777 Med. 2018;7(11):400. doi:10.3390/jcm7110400. 777 Med. 2018;7(11):400. doi:10.3390/jcm7110400.
778 90. Chen L, Li X, Chen M, Feng Y, Xiong C. The
- 778 90. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicated new potential
779 mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-779 mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-780 1100. doi:10.1093/cvr/cvaa078. 780 1100. doi:10.1093/cvr/cvaa078.
781 91. Heather LC, Clarke K. Metabol
- 781 91. Heather LC, Clarke K. Metabolism, hypoxia, and the diabetic heart. J Mol Cell Cardiol. 2011;50(4):598-
782 605. doi:10.1016/j.yimcc.2011.01.007. 782 605. doi:10.1016/j.yjmcc.2011.01.007.
783 92. Iabal T. Welsby PJ. Howarth FC.
- ⁷⁸³92. Iqbal T, Welsby PJ, Howarth FC, Bidasee K, Adeghate E, Singh J. Effects of diabetes-induced 784 hyperglycaemia in the heart: biochemical and structural alterations. In: Turan B, Dhalla N, editors. Diabetic
785 Cardiomyopathy: Advances in Biochemistry in Health and Disease, vol 9. New York: Springer; 2014. 785 Cardiomyopathy: Advances in Biochemistry in Health and Disease, vol 9. New York: Springer; 2014.
786 SBN:9781461493174. ⁷⁸⁶ISBN:9781461493174.
- 787 93. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013:17(1):20-33. doi:10.1016/i.cmet.2012.11.012. 788 factors. Cell Metab. 2013;17(1):20-33. doi:10.1016/j.cmet.2012.11.012.